Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus

Antiviral Research

Volumn 151, Issue , 2018, Pages 97-104

  Bixler, Sandra L ^a   Bocan, Thomas M ^a   Wells, Jay ^a   Wetzel, Kelly S ^a   Van Tongeren, Sean A ^a   Dong, Lian ^a   Garza, Nicole L ^a   Donnelly, Ginger ^a   Cazares, Lisa H ^a   Nuss, Jonathan ^a   Soloveva, Veronica ^a   Koistinen, Keith A ^a   Welch, Lisa ^a,b   Epstein, Carol ^b   Liang, Li Fang ^b   Giesing, Dennis ^b   Lenk, Robert ^b   Bavari, Sina ^a   Warren, Travis K ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b FUJIFILM Pharmaceuticals USA   (United States)

Author keywords

Ebola; Favipiravir; Marburg; Nonhuman primates; T 705; Therapeutic

Indexed keywords

FAVIPIRAVIR; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BIOSAFETY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; FEMALE; IN VIVO STUDY; LOADING DRUG DOSE; MACACA FASCICULARIS; MALE; MARBURG HEMORRHAGIC FEVER; MARBURGVIRUS; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ANIMAL; BLOOD; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; PATHOLOGY; PRIMATE; SURVIVAL ANALYSIS; VIROLOGY; VIRUS LOAD;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; MALE; MARBURG VIRUS DISEASE; MARBURGVIRUS; PRIMATES; PYRAZINES; RNA, VIRAL; SURVIVAL ANALYSIS; VIRAL LOAD;

EID: 85041549017     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.12.021     Document Type: Article

References (23)

1. Bai, C.Q., Mu, J.S., Kargbo, D., Song, Y.B., Niu, W.K., Nie, W.M., Kanu, A., Liu, W.W., Wang, Y.P., Dafae, F., et al. Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clin. Infect. Dis. 63:10 (2016), 1288–1294.
2. Bente, D., Gren, J., Strong, J.E., Feldmann, H., Disease modeling for Ebola and Marburg viruses. Dis. Model. Mech. 2:1–2 (2009), 12–17.
3. Bixler, S.L., Bocan, T.M., Wells, J., Wetzel, K., Van Tongeren, S., Lackemeyer, N., Donnelly, G., Cazares, L., Soloveva, V., Welch, L., et al. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with ebola virus. Antivir. Res., 2017.
4. Furuta, Y., Gowen, B.B., Takahashi, K., Shiraki, K., Smee, D.F., Barnard, D.L., Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:2 (2013), 446–454.
5. Geisbert, T.W., Pushko, P., Anderson, K., Smith, J., Davis, K.J., Jahrling, P.B., Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8:5 (2002), 503–507.
6. Julander, J.G., Smee, D.F., Morrey, J.D., Furuta, Y., Effect of T-705 treatment on western equine encephalitis in a mouse model. Antivir. Res. 82:3 (2009), 169–171.
7. Julander, J.G., Shafer, K., Smee, D.F., Morrey, J.D., Furuta, Y., Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 53:1 (2009), 202–209.
8. Madelain, V., Guedj, J., Mentre, F., Nguyen, T.H., Jacquot, F., Oestereich, L., Kadota, T., Yamada, K., Taburet, A.M., de Lamballerie, X., et al. Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob. Agents Chemother., 61(1), 2017.
9. Marburg virus disease - Uganda. http://www.who.int/csr/don/25-october-2017-marburg-uganda/en/.
10. Mentre, F., Taburet, A.M., Guedj, J., Anglaret, X., Keita, S., de Lamballerie, X., Malvy, D., Dose regimen of favipiravir for Ebola virus disease. Lancet Infect. Dis. 15:2 (2015), 150–151.
11. Mora-Rillo, M., Arsuaga, M., Ramirez-Olivencia, G., de la Calle, F., Borobia, A.M., Sanchez-Seco, P., Lago, M., Figueira, J.C., Fernandez-Puntero, B., Viejo, A., et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 3:7 (2015), 554–562.
12. Morrey, J.D., Taro, B.S., Siddharthan, V., Wang, H., Smee, D.F., Christensen, A.J., Furuta, Y., Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antivir. Res. 80:3 (2008), 377–379.
13. Nguyen, T.H., Guedj, J., Anglaret, X., Laouenan, C., Madelain, V., Taburet, A.M., Baize, S., Sissoko, D., Pastorino, B., Rodallec, A., et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl. Trop. Dis., 11(2), 2017, e0005389.
14. Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Olschlager, S., et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl. Trop. Dis., 8(5), 2014, e2804.
15. Oestereich, L., Ludtke, A., Wurr, S., Rieger, T., Munoz-Fontela, C., Gunther, S., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir. Res. 105 (2014), 17–21.
16. Pushko, P., Bray, M., Ludwig, G.V., Parker, M., Schmaljohn, A., Sanchez, A., Jahrling, P.B., Smith, J.F., Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect Guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:1 (2000), 142–153.
17. Schibler, M., Vetter, P., Cherpillod, P., Petty, T.J., Cordey, S., Vieille, G., Yerly, S., Siegrist, C.A., Samii, K., Dayer, J.A., et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect. Dis. 15:9 (2015), 1034–1040.
18. Shurtleff, A.C., Bavari, S., Animal models for ebolavirus countermeasures discovery: what defines a useful model?. Expert Opin. Drug Discov. 10:7 (2015), 685–702.
19. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., Danel, C., et al. Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med., 13(3), 2016, e1001967.
20. Smee, D.F., Tarbet, E.B., Furuta, Y., Morrey, J.D., Barnard, D.L., Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol. 8:11 (2013), 1085–1094.
21. Smither, S.J., Eastaugh, L.S., Steward, J.A., Nelson, M., Lenk, R.P., Lever, M.S., Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104 (2014), 153–155.
22. Warren, T.K., Trefry, J.C., Marko, S.T., Chance, T.B., Wells, J.B., Pratt, W.D., Johnson, J.C., Mucker, E.M., Norris, S.L., Chappell, M., et al. Euthanasia assessment in ebola virus infected nonhuman primates. Viruses 6:11 (2014), 4666–4682.
23. Warren, T.K., Whitehouse, C.A., Wells, J., Welch, L., Charleston, J.S., Heald, A., Nichols, D.K., Mattix, M.E., Palacios, G., Kugleman, J.R., et al. Delayed time-to-treatment of an antisense Morpholino Oligomer is effective against lethal Marburg virus infection in cynomolgus macaques. PLoS Negl. Trop. Dis., 10(2), 2016, e0004456.